MOUNTAIN VIEW, Calif., July 26, 2011 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the second quarter ended June 30, 2011 after the NASDAQ Market closes on Monday, August 1, 2011.
The company will conduct a conference call and an audio webcast at 1:30pm PT on the same day.
Date: August 1, 2011
Time: 1:30 PM PT
Listen via Internet: http://ir.vivus.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=49013&k=829952BA
Toll-free: 877-359-2916
International: 224-357-2386
A webcast replay will be available on the VIVUS web site for 30 days.
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by U.S. and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.